Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 28, 2020
Daily News
October 28, 2020
- Copay Rose for Some Patients as Leuplin Issue Triggered Shortage of 6-Month Depot: HCPs
October 28, 2020
- 1st Patient Enrolled in Global COVID-19 Study for Eritoran, Apremilast
October 28, 2020
- Bill to Amend Immunization Act Submitted to Diet
October 28, 2020
- Opdivo Plus Cabometyx Filed for RCC in Japan: Ono/Takeda
October 28, 2020
- MHLW Issues Notification on Establishing COVID-19 Vaccination Systems
October 28, 2020
- Opdivo-Yervoy Pair Filed for Malignant Pleural Mesothelioma in Japan
October 28, 2020
- Eisai Snaps Up Worldwide Rights for All of Cogstatethe’s Cognitive Function Tests
October 28, 2020
- Takeda Files Japan NDA for Short Bowel Syndrome Drug
October 28, 2020
- Sumitomo Dainippon Links Up with US Health Tech for R&D on Blood Collection and Stabilization Device
October 28, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…